Canada’s health regulator on Wednesday approved Pfizer’s COVID-19 vaccine, making it the third country to authorize the use of the shot – as the green-lighting of the vaccine in the US is still at least another day away.
WASHINGTON — The coronavirus vaccine made by Pfizer and BioNTech provides strong protection against Covid-19 within about 10 days of the first dose, according to documents published on Tuesday by the Food and Drug Administration before a meeting of its vaccine advisory group.
The finding is one of several significant new results featured in the briefing materials, which include more than 100 pages of data analyses from the agency and from Pfizer. Last month, Pfizer and BioNTech announced that their two-dose vaccine had an efficacy rate of 95 percent after two doses administered three weeks apart. The new analyses show that the protection starts kicking in far earlier.
Trump administration officials passed when Pfizer offered in late summer to sell the U.S. government additional doses of its Covid-19 vaccine, according to people familiar with the matter. Now Pfizer may not be able provide more of its vaccine to the United States until next June because of its commitments to other countries, they said.
As the administration scrambles to try to purchase more doses of the vaccine, President Trump plans on Tuesday to sign an executive order “to ensure that United States government prioritizes getting the vaccine to American citizens before sending it to other nations,” according to a draft statement and a White House official, though it was not immediately clear what force the president’s executive order would carry.
That included whether it would expand the U.S. supply of doses beyond what is spelled out in existing federal contracts.
Recent Comments